Alnylam Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ALNY

Comments

Alnylam Pharmaceuticals Inc Earnings Estimates

ALNYNASDAQ

Trade with Public

$333.39

-6.02-1.77%

At close: Apr 14, 5:00 PM EST

$333.39

-6.02-1.77%

Pre-Market: 6:01 AM EST

Overview NewsEarningsOptions Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Alnylam Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) is scheduled to report Q1 earnings on April 30, 2026. Analysts estimate EPS of $1.29 and quarterly revenue of $1.12B.

In the most recent quarter (Q4), Alnylam Pharmaceuticals reported EPS of $1.25, beating estimates of $1.20 by 0.04%. Revenue came in at $1.10B, missing the estimate of $1.15B by 0.05%.

Alnylam Pharmaceuticals has beaten EPS estimates in 8 consecutive quarters.

Over the last 4 quarters, Alnylam Pharmaceuticals has averaged an EPS surprise of 1.35% and a revenue surprise of 0.12%.

Earnings Date

Apr 30

EPS Estimate

$1.290

Quarterly Revenue Estimate

$1.12B

Annual Revenue
(as of Dec 31)

$3.71B

Alnylam Pharmaceuticals Earnings History

Analyze the earnings history of Alnylam Pharmaceuticals using advanced sorting and filters.

Loading calendar...

Alnylam Pharmaceuticals (ALNY) Earnings Per Share

The chart below shows Alnylam Pharmaceuticals's reported EPS compared to analyst estimates over recent quarters.

Alnylam Pharmaceuticals (ALNY) Revenue

The chart below shows Alnylam Pharmaceuticals's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Alnylam Pharmaceuticals (NASDAQ:ALNY) reporting earnings?

Alnylam Pharmaceuticals (ALNY) is scheduled to report earnings on April 30, 2026. The last reported earnings were for reported on February 12, 2026 for Q4.

What were the latest earnings per share (EPS) for Alnylam Pharmaceuticals (NASDAQ:ALNY)?

The Actual EPS was $1.25, which beat the estimate of $1.20.

What were Alnylam Pharmaceuticals’s (NASDAQ:ALNY) revenues?

The Actual Revenue was $1.10B, which missed the estimate of $1.15B.

People Also Watch

Neurocrine Biosciences Inc

NASDAQ:NBIX

$131.44

Ionis Pharmaceuticals Inc

United Therapeutics Corp

Alnylam Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) is scheduled to report Q1 earnings on April 30, 2026. Analysts estimate EPS of $1.29 and quarterly revenue of $1.12B.

In the most recent quarter (Q4), Alnylam Pharmaceuticals reported EPS of $1.25, beating estimates of $1.20 by 0.04%. Revenue came in at $1.10B, missing the estimate of $1.15B by 0.05%.

Alnylam Pharmaceuticals has beaten EPS estimates in 8 consecutive quarters.

Over the last 4 quarters, Alnylam Pharmaceuticals has averaged an EPS surprise of 1.35% and a revenue surprise of 0.12%.

Earnings Date

Apr 30

EPS Estimate

$1.290

Quarterly Revenue Estimate

$1.12B

Annual Revenue
(as of Dec 31)

$3.71B